SYSTEMIC XXXX INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open-Label Study Using Canakinumab.

@entity1 @entity4051 @entity6 @entity1356 @entity1103 @entity1829
PURPOSE: To evaluate the effect of systemic @entity1356 inhibition using canakinumab (Ilaris) on retinal neovascularizations in @entity6 . METHODS: @entity1 with @entity6 were enrolled in a prospective uncontrolled pilot study. Canakinumab (150 mg) was given 3 times subcutaneously. The primary end point was the change in the area of neovascularization from baseline to Week 24. Secondary end points were the change in @entity1829 measured and best-corrected visual acuity (BCVA), as well as systemic safety evaluation, HbA1c, and systemic inflammatory parameters. RESULTS: Systemic canakinumab treatment was well tolerated. None of the 8 eyes showed progression of neovascularizations within 24 weeks. Their mean size remained unchanged comparing 0.60 mm at baseline with 0.62 mm at Week 24 (P = 0.944). Median BCVA remained stable with 80 ETDRS letters at baseline and 82 ETDRS letters at Week 24. A not statistically significant @entity1829 was detectable for the foveal central subfield thickness (mean, 313-295  m). Mean @entity4051 c improved significantly from 7.92% to 7.30% within the 24 weeks (P = 0.046). Systemic inflammatory parameters remained overall unchanged. CONCLUSION: Systemic canakinumab showed no change in neovascularizations in @entity6 . Promising effects were seen on @entity1103 .
